Four fresh SEC Form D filings landed this week, totaling over $379M in new capital. Here's the roundup — sourced straight from EDGAR, scored for B2B sales relevance.
The raises
Entera Bio Ltd. — $275.0M (Biotechnology, score 98/100)
The biggest raise of the week by a wide margin. Biotech companies at this stage are usually staffing up fast — clinical ops tooling, compliance software, lab equipment vendors should be watching.
Petfolk Inc. — $40.0M
Pet care keeps quietly pulling in serious capital. A raise like this usually means new locations, new headcount, and a fresh vendor budget before the usual outreach even starts.
Abcuro, Inc. — $39.4M (Biotechnology)
Another clinical-stage raise. If you sell into biotech, this is exactly the kind of signal that's easy to miss if you're not watching EDGAR directly.
Bitzero Holdings Inc. — $24.8M
Rounding out the week — a smaller but still-actionable raise for anyone doing targeted outbound.
Why this matters for sales teams
A company that just raised has budget it didn't have last month, and no vendor relationships locked in yet. That window closes fast, usually within a few weeks, once the usual outbound machines catch on. Most teams find out about these rounds from TechCrunch, weeks after the money already landed and the obvious vendors already got there first.
We built Funding Signals to close that gap: every SEC Form D filing, pulled the day it's filed, enriched and scored for B2B sales relevance. No manual EDGAR digging, no stale funding newsletters.
Free tier available, no card required.
